Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update

David Wojciechowski
Flavio Vincenti
Kidney Transplant Service, University of California, San Francisco, CA, USA

Abstract: In June 2011, the US Food and Drug Administration approved belatacept for the prophylaxis of organ rejection in adult kidney transplant recipients. This review discusses the use of belatacept for the prevention of acute rejection as part of a maintenance immunosuppression regimen. Belatacept is a selective costimulation blocker designed to provide effective immunosuppression while avoiding the toxicities associated with calcineurin inhibitors. Phase III trial data have demonstrated that belatacept is noninferior to cyclosporine in 1-year patient and allograft survival. Three-year data demonstrate an ongoing improvement in mean measured glomerular filtration rate in belatacept-treated versus cyclosporine-treated patients. However, the rate of acute rejection was higher in belatacept-treated patients compared with cyclosporine. Specifically, there was a higher incidence of Banff type II rejections in patients treated with belatacept. Despite the higher Banff grade, rejections on belatacept were not associated with other factors associated with poor outcomes, such as the development of donor-specific antibodies or reduced estimated glomerular filtration rate. One safety issue that must be considered when using belatacept is the potential for increased risk of post-transplant lymphoproliferative disease. There were more cases of post-transplant lymphoproliferative disease in belatacept-treated patients, especially in recipients seronegative for Epstein–Barr virus or patients treated with lymphocyte-depleting agents. Therefore, belatacept can be recommended for use in Epstein–Barr virus antibody-positive recipients.

Keywords: belatacept, kidney transplant, acute rejection

Introduction
The introduction of calcineurin inhibitors (CNI) followed by mycophenolate mofetil resulted in an era of improved efficacy of maintenance immunosuppression. Short-term acute rejection rates declined and 1-year outcomes improved. Despite short-term success, the long-term renal allograft survival has not shown a similar rate of improvement.1 The 1-year renal allograft survival rate is 95% and 89% for recipients of living and deceased donor kidneys, respectively.2 At 5 years post-transplantation, renal allograft survival falls to a disappointing 80% and 67% for living and deceased donor kidney recipients, respectively.2

Cardiovascular disease remains the leading cause of death post-transplantation,2 while chronic allograft nephropathy (a nonspecific term) remains the most common cause of late allograft loss.3 With the introduction of immunosuppression protocols which include a CNI, the data have suggested that CNIs are a significant contributor to the progression of chronic allograft nephropathy and hasten long-term allograft loss.4 Given the concern about long-term CNI exposure on renal function, strategies...
have evolved to eliminate or reduce CNI exposure as the acute rejection risk declines over time. However, newer data suggest that perhaps it is not a direct CNI effect but rather a subacute, chronic alloimmune response (such as that occurring with the development of donor-specific antibodies) that is playing a dominant role in late allograft loss. Strategies to minimize CNI exposure post-transplantation may contribute to this effect.

Belatacept (Nulojix®, Bristol-Myers Squibb, Princeton, NJ), a fusion protein and selective costimulation blocker, was approved in June 2011 by the US Food and Drug Administration for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. It is given as a 30-minute infusion, which can be done either in an infusion center or in the home. Belatacept was developed to provide effective immunosuppression as an alternative to CNIs and thus avoid the toxicities associated with CNIs. This review summarizes the outcome data, with an emphasis on acute rejection, from the clinical trials of belatacept in renal transplant recipients as part of a CNI-free regimen.

**Costimulation blockade with belatacept**

The CD28/B7 (CD80 and 86) costimulation pathway (Figure 1) is an essential signal for T-cell activation. It is one of several T-cell costimulatory pathways that are required to regulate the different T-cell responses in transplant models. After 25 years of research, the fusion receptor protein, CTLA4-Ig (abatacept), a competitive antagonist for CD28 blocking CD80/CD86 binding, was approved for human use in the treatment of rheumatoid arthritis. Early experiments with costimulation blockade in transplantation were mixed. Prolongation of graft survival or induction of tolerance using costimulation blockade in rodent transplantation experiments could not be reproduced in nonhuman primates. CTLA4-Ig did not achieve as good affinity with CD86 as with CD80 and was the likely cause of failure in a more stringent animal model.

Belatacept, a reengineered CTLA4-Ig with two amino acid substitutions in the CTLA4 binding domains, binds CD80 two-fold better and CD86 four-fold better than CTLA4-Ig and provides 10-fold more potent inhibition of T-cell activation in vitro versus CTLA4-Ig. The in vitro superiority of belatacept in blocking T-cell responses was confirmed by better survival of renal allografts in a nonhuman primate model. In these experiments, a CNI-free regimen with belatacept and a combination of an anti-interleukin-2 receptor antibody and maintenance therapy with mycophenolate mofetil and steroids resulted in marked prolongation of survival of renal allografts.

Given these encouraging data, clinical trials were undertaken, and the initial Phase II data was published in 2005. In this multicenter trial, which compared the safety and efficacy of two dosing regimens of belatacept versus cyclosporine, belatacept was found to be noninferior (with a noninferior margin set at 20%) to cyclosporine as a means of preventing acute rejection after renal transplantation, with five (7%) and four (6%) patients treated with a more intensive (MI) and less intensive (LI) belatacept regimen, respectively, experiencing acute rejection at 6 months compared with six (8%) cyclosporine-treated patients. In regard to safety, it was also noted that three patients receiving the MI regimen developed post-transplant lymphoproliferative disorder (PTLD) compared with one patient receiving cyclosporine. Two of these patients developed PTLD after belatacept had been replaced with conventional immunosuppression (tacrolimus, mycophenolate mofetil, and corticosteroids). Two of the three patients had primary Epstein-Barr virus (EBV) infections, while the third received lymphocyte-depleting therapy with murinomab-CD3 for acute rejection. In the 5-year long-term extension trial, one patient treated with cyclosporine developed PTLD in year 4 after transplantation, compared with no patients treated with belatacept.

**Phase III trials: BENEFIT and BENEFIT-EXT**

Given the promising Phase II trial results, two Phase III trials were undertaken. Both trials have provided important data on the role of belatacept for the prevention of acute rejection as part of a CNI-free regimen.

**BENEFIT**

The first study, Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT), was a multicenter, randomized,
active-controlled, parallel-group Phase III trial. Adult patients receiving a living donor or standard criteria deceased donor kidney were eligible. First-time patients with a panel reactive antibody $\geq 50\%$, retransplants with a panel-reactive antibody $\geq 30\%$, recipients of prior or concurrent nonrenal solid organ transplants, and recipients of extended criteria donor kidneys were excluded. Patients were randomized to one of three regimens for maintenance immunosuppression, ie, a MI regimen of belatacept, a LI regimen of belatacept, or cyclosporine (Figure 2). Patients in all treatment arms received basiliximab induction and were maintained on mycophenolate mofetil and corticosteroids. Lymphocyte-depleting therapy was permitted in the cyclosporine group for delayed or anticipated delayed graft function. Patients with acute rejection $\geq$ Grade IIB could be treated with T-cell-depleting therapy at the investigator’s discretion.

The trial was designed with three coprimary outcomes, ie, composite patient and graft survival, a composite renal impairment endpoint, and incidence of acute rejection. The noninferiority margin for patient and graft survival and for acute rejection was set at 10% and 20%, respectively. Protocol biopsies were performed at implantation and at week 52. A total of 527 patients were randomized to three treatment groups, transplanted, and completed the initial 12-month treatment phase. Recipient demographics and baseline characteristics as well as donor characteristics were similar between the three groups.

Both belatacept regimens were noninferior to cyclosporine for the primary endpoint of patient and graft survival. At 1 year, patients enrolled in the MI, LI, and cyclosporine treatment groups had 95%, 97%, and 93% patient and graft survival, respectively. The mean measured glomerular filtration rate (GFR) was 65 mL/min/1.73 m$^2$, 63.4 mL/min/1.73 m$^2$, and 50.4 mL/min/1.73 m$^2$ in the MI-treated, LI-treated, and cyclosporine-treated patients, respectively ($P < 0.0001$ for both MI and LI versus cyclosporine). The prevalence of chronic allograft nephropathy on protocol biopsies was lower in belatacept-treated patients compared with cyclosporine-treated patients (18% MI, 24% LI, 32% cyclosporine).

There was a higher incidence of acute rejection at 12 months in the belatacept-treated groups compared with the cyclosporine-treated group (22% MI, 17% LI, 7% cyclosporine). The incidence of acute rejection met the noninferiority cutoff for the LI group versus the cyclosporine group, but not for the MI group versus the cyclosporine group. Almost 100% of these rejections occurred within the first 6 months post-transplantation. Belatacept-treated patients had more type IIa and IIb rejections compared with cyclosporine-treated patients but were not associated with an increase in donor-specific antibody. The mean measured GFR at month 12 was higher in belatacept-treated patients with acute rejection compared with cyclosporine-treated patients without acute rejection (Figure 3).

Figure 2  All patients received induction with basiliximab and maintenance therapy with mycophenolate mofetil and corticosteroids.
Notes: Patients randomized to receive cyclosporine were started at 7 ± 3 mg/kg daily in divided doses with a goal trough of 150–300 ng/mL for the first month followed by 100–250 ng/mL thereafter. MI-treated patients received belatacept at 10 mg/kg for the first 168 days and 5 mg/kg from day 196 onwards. LI-treated patients received belatacept at 10 mg/kg for the first 84 days and 5 mg/kg from day 112 onward. *All patients received basiliximab induction, mycophenolate mofetil, and corticosteroid-taper.
Belatacept-treated patients had a significantly lower mean blood pressure (MI 133/79 mmHg, LI 131/79 mmHg) compared with cyclosporine-treated patients (139/82 mmHg, \( P \leq 0.0273 \) for MI or LI versus cyclosporine in all comparisons). The mean change in non-high-density lipoprotein cholesterol from baseline was significantly different in belatacept-treated patients (MI 0.21 mmol/L, LI 0.21 mmol/L) compared with cyclosporine-treated patients (0.47 mmol/L, \( P = 0.0115 \) for MI and \( P = 0.0104 \) for LI versus cyclosporine). The incidence of new-onset diabetes mellitus after transplant (NODAT) was not significantly different between the three groups, ie, MI 7%, LI 4%, and cyclosporine 10% (\( P = NS \) for MI or LI versus cyclosporine).

Two-year and 3-year data are available for BENEFIT.\(^{24,25}\) Between months 12 and 24, a total of eight patients had an acute rejection episode (MI, \( n = 4 \); cyclosporine, \( n = 4 \)) for a total of 24% (MI) and 9% (cyclosporine) from baseline to month 24.\(^{24}\) The 3-year data demonstrate that there were no new cases of acute rejection in the belatacept groups from year 2 to year 3.\(^{25}\) However, one patient in the cyclosporine group experienced acute rejection after year 2. By year 3, donor-specific antibodies occurred more commonly in cyclosporine-treated patients (MI 6%, LI 15%, cyclosporine 11%). In patients who had an acute rejection episode by year 3, the proportion of patients with donor-specific antibodies was 12% (MI), 8% (LI), and 19% (cyclosporine). In regard to renal function at year 3, the mean calculated GFR was 65.2 ± 26.3 mL/min/1.73 m\(^2\) (MI), 65.8 ± 27.0 mL/min/1.73 m\(^2\) (LI), and 44.4 ± 23.6 mL/min/1.73 m\(^2\) (cyclosporine, \( P < 0.0001 \) MI or LI versus cyclosporine). The mean calculated GFR in belatacept-treated patients was consistently higher compared with cyclosporine-treated patients throughout the study period.

The issue of PTLD, which was raised in the Phase II trial, also merits a discussion from the Phase III data. By 12 months, one patient, two patients, and one patient in the MI, LI, and cyclosporine groups developed PTLD, respectively. Additionally, between years 1 and 2, two additional patients in the MI group developed PTLD affecting the central nervous system. Four of the six patients who developed PTLD had known risk factors. One patient had EBV-negative serology pretransplant, one patient received lymphocyte-depleting therapy as treatment for an acute rejection, and two patients had EBV-negative serology and received lymphocyte-depleting therapy. Lastly, two patients with EBV-negative serology received transplants from EBV-seropositive donors. No new cases of PTLD were reported in any group between years 2 and 3.\(^{25}\)

BENEFIT-EXT

The second study was the Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial-EXTended criteria donors (BENEFIT-EXT),\(^{26}\) a randomized, multicenter Phase III trial conducted in patients who received a kidney transplant from an extended criteria donor defined as: aged \( \geq 60 \) years; aged \( \geq 50 \) years with at least two other risk factors (cerebrovascular accident, hypertension, serum creatinine \( > 132.6 \) \( \mu \text{mol/L} \)); anticipated cold ischemia time \( \geq 24 \) hours; or donation after cardiac death. Patients were treated with basiliximab induction, mycophenolate mofetil, and corticosteroids, and were then randomized to receive either belatacept MI, belatacept LI, or cyclosporine. Lymphocyte-depleting therapy was allowed for anticipated delayed graft function in cyclosporine-treated patients. Patients with acute rejection \( \geq \text{Grade IIB} \) could be treated with T-cell-depleting therapy at the investigators’ discretion.

The primary outcomes were the composite endpoint of patient and graft survival as well as the composite endpoint of renal impairment at 12 months. Note that unlike BENEFIT, BENEFIT-EXT did not include the incidence of acute rejection as a primary outcome measure. The noninferiority margin was set at 10% for patient and graft survival. Secondary outcomes included measured GFR, calculated GFR using the Modification of Diet in Renal Disease equation, prevalence of biopsy-proven chronic allograft nephropathy, and incidence and severity of biopsy-proven acute rejection. Protocol biopsies were performed at implantation and at week 52. A total of 543 patients were randomized and transplanted (\( n = 184 \) MI, \( n = 175 \) LI, \( n = 184 \) cyclosporine). There were no differences in baseline characteristics between the three groups.
Both belatacept regimens were noninferior to cyclosporine on the primary endpoint of patient and graft survival. Graft loss or death occurred in 14%, 11%, and 15% of patients treated with MI, LI, and cyclosporine, respectively. The prevalence of biopsy-proven chronic allograft nephropathy was similar between the three groups (MI 45%, LI 46%, cyclosporine 52%). The mean measured GFR at 12 months was 52.1 mL/min/1.73 m² (P = 0.0083 versus cyclosporine), 49.5 mL/min/1.73 m² (P = 0.1039 versus cyclosporine), and 45.2 mL/min/1.73 m² for the MI-treated, LI-treated, and cyclosporine-treated groups, respectively. The difference in measured GFR was significantly better in the MI-treated patients versus the cyclosporine-treated patients (P = 0.0083) but was not significantly different for the LI group compared with cyclosporine (P = 0.1039).

Mean systolic and diastolic blood pressure was lower for both belatacept groups compared with the cyclosporine-treated group (MI 141/78 mmHg, LI 141/78 mmHg, cyclosporine 150/82 mmHg). The incidence of NODAT was significantly lower in the MI group compared with the cyclosporine group (MI 2% versus cyclosporine 9%, P = 0.0308). However, there was no significant difference in NODAT in the LI group compared with cyclosporine (LI 5%, P = 0.2946). The mean change in non-high-density lipoprotein cholesterol from baseline was significantly different in the MI (0.33 mmol/L) and LI (0.29 mmol/L) groups compared with cyclosporine (0.76 mmol/L, P = 0.0016 MI versus cyclosporine; P = 0.0006 LI versus cyclosporine).

There was no significant difference in the incidence of acute rejection between the three groups (MI 17.9%, LI 17.7%, cyclosporine 14.1%). However, more type IIB rejections occurred in belatacept-treated patients compared with cyclosporine-treated patients (MI 9%, LI 5%, cyclosporine 3%). The majority of rejections occurred within the first 3 months (81%), and nearly all occurred within 6 months. The numbers were small, but it should be noted that more patients in the MI group (n = 5) experienced more than one episode of acute rejection compared with the LI (n = 1) and cyclosporine (n = 2) groups. The most common treatment for acute rejection was corticosteroids, whereas T-cell-depleting therapy was used in 13, five, and four patients in the MI, LI, and cyclosporine groups, respectively.

Three-year data are now available for BENEFIT-EXT. One patient in each treatment group experienced acute rejection after year 2. By 3 years, the rate of acute rejection was 18%, 19%, and 16% for MI-treated, LI-treated, and cyclosporine-treated patients, respectively. Similar to what was found in the BENEFIT study, the development of donor-specific antibodies was lower in belatacept-treated patients. At baseline, the presence of donor-specific antibodies was similar and low across the treatment groups (6% MI, 5% LI, and 8% cyclosporine). The incremental increase in donor-specific antibodies occurred at a lower frequency in belatacept-treated patients compared with cyclosporine-treated patients by year 3 (MI 7%, LI 6%, and cyclosporine 15%). Among those who had acute rejection, the frequency of donor-specific antibodies was 9% (MI), 6% (LI), and 26% (cyclosporine). In regard to renal function at 3 years, the mean calculated GFR in the intention-to-treat population was 42.7 ± 27.6 mL/min/1.73 m², 42.2 ± 25.2 mL/min/1.73 m², and 31.5 ± 22.1 mL/min/1.73 m² in MI-treated, LI-treated, and cyclosporine-treated patients. To look at this another way, compared with cyclosporine, both belatacept regimens had more patients with calculated GFR values within chronic kidney disease (CKD) stages 1 and 2 (31% MI and 22% LI versus 8% cyclosporine) and fewer patients within stages 4 and 5 (30% MI and 27% LI versus 44% cyclosporine, Figure 4). This is an important issue because the higher intercept GFR seen in the belatacept-treated patients may translate into improved long-term allograft outcome.

One patient (0.5%) in the MI group and two patients (1%) in the LI group developed PTLD during the 12-month follow-up period. One additional patient in each of the belatacept groups developed PTLD after month 12. Three of the five PTLD patients had negative EBV serology pretransplant. None of the patients who developed PTLD were exposed to lymphocyte-depleting therapy. By 3 years, PTLD was reported in two MI patients and three LI patients; four cases involved the central nervous system and one case (LI) involved the renal allograft and lymph nodes. Four additional cases of PTLD (three LI and one cyclosporine) occurred after 3 years; one case involved the central nervous system (LI), one involved the renal allograft (LI), one involved the gastrointestinal tract (LI), and the other involved bone marrow (cyclosporine).

Rejection on belatacept
In various studies, certain features of acute rejection episodes have been found to be poor prognostic factors for graft outcome. These features include high Banff grade, association with development of donor-specific antibodies, late rejection, poor renal function after rejection, and recurrent rejection episodes. Belatacept was associated with more rejections that were histologically more severe (higher Banff grade) than cyclosporine-treated patients, but lacked the other characteristics usually associated with poor outcomes.
There are several possible factors that may help explain the trend of higher rejection rates seen in belatacept-treated patients. Some studies have suggested that memory cells may be resistant to costimulation blockade. Recent data suggest that resistance of memory T-cells to costimulatory blockade can be abrogated when costimulatory blockade is coupled with either anti-VLA-4 (very late antigen-4) or anti-LFA-1 (leukocyte functional antigen-1) antibody blockade. Both integrins (VLA-4 and LFA-1) play a central role in T-cell activation, effector functions, and trafficking to inflamed tissues. Additionally, T-cell activation may also occur through other costimulation pathways.

It is interesting that the LI regimen in the BENEFIT study was associated with a lower rate of acute rejection compared with the MI regimen. The data suggest that blockade of CD80/86 on the antigen-presenting cell may interfere with the negative signaling that occurs through CTLA-4 engagement and may be required to curtail alloresponses. As an example, in a Phase II trial utilizing CTLA4Ig in patients with psoriasis, the humoral immune response to keyhole limpet hemocyanin immunization was blunted with lower doses of CTLA4Ig but not with the highest dose.

Lastly, there may be the depletion of important subsets of T regulatory cells. Data have suggested that patients treated chronically with belatacept maintained normal T regulatory cells; it remains unclear if a subset of adaptive T regulatory cells may have been adversely affected.

### Safety: focus on PTLD

The major safety concern that has arisen is the development of PTLD in belatacept-treated patients. An integrated safety profile analysis was performed utilizing data from the Phase II trial as well as data from BENEFIT and BENEFIT-EXT. The pooled analysis included a total of 1425 patients (MI 477, LI 472, cyclosporine 476). The frequency of malignancies was 10%, 6%, and 7% in the MI, LI, and cyclosporine groups, respectively (Table 1). Sixteen cases of PTLD occurred (n = 8 MI, n = 6 LI, n = 2 cyclosporine), including nine cases involving the central nervous system (n = 6 MI, n = 3 LI). The risk of PTLD was highest in EBV-negative recipients. Additionally, more PTLD affecting the central nervous system occurred in the MI group. Consequently, when belatacept was approved by the Food and Drug Administration, it was recommended for use only in patients who are seropositive.

### Table 1

Incidence of malignancies and PTLD in the pooled analysis from the Phase II and III belatacept trials

<table>
<thead>
<tr>
<th></th>
<th>Belatacept MI (n = 477)</th>
<th>Belatacept LI (n = 472)</th>
<th>Cyclosporine (n = 476)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All malignancies</td>
<td>46 (10)</td>
<td>27 (6)</td>
<td>34 (7)</td>
</tr>
<tr>
<td>PTLD</td>
<td>8 (2)</td>
<td>6 (1)</td>
<td>2 (&lt;1)</td>
</tr>
<tr>
<td>Malignancies excluding nonmelanoma skin cancer</td>
<td>30 (6)</td>
<td>21 (4)</td>
<td>20 (4)</td>
</tr>
<tr>
<td>Nonmelanoma skin cancer</td>
<td>17 (4)</td>
<td>7 (2)</td>
<td>15 (3)</td>
</tr>
</tbody>
</table>

**Note:** Values are presented as n (%).

**Abbreviations:** LI, less intensive; MI, more intensive; PTLD, post-transplant lymphoproliferative disease.
for EBV. Additionally, it should be noted that only the LI regimen was approved by the Food and Drug Administration for kidney transplant rejection prophylaxis. Lastly, one can abrogate the PTLD risk by avoiding the use of lymphocyte-depleting agents to treat acute rejection.

**Belatacept and cardiometabolic risk**

An analysis was recently published evaluating the effect of belatacept compared with cyclosporine on cardiovascular and metabolic risk factors. The analysis included 1209 patients from BENEFIT and BENEFIT-EXT and assessed the cardiovascular and metabolic endpoints (changes in blood pressure, changes in serum lipids, and incidence of NODAT) at month 12. Mean systolic blood pressure was 6–9 mmHg lower and mean diastolic blood pressure was 3–4 mmHg lower in the MI and LI groups versus cyclosporine (\( P < 0.002 \)) across both studies at month 12. Non-high-density lipoprotein cholesterol was lower in the belatacept groups versus cyclosporine (\( P < 0.01 \) MI or LI versus cyclosporine in each study). Serum triglycerides were lower in the belatacept groups versus cyclosporine (\( P < 0.02 \) MI or LI versus cyclosporine in each study). In a pooled data analysis, NODAT occurred less often in the belatacept groups versus cyclosporine (\( P < 0.05 \) MI or LI versus cyclosporine in each study). When one considers the impact of chronic allograft nephropathy on allograft loss and the effect of hypertension, hyperlipidemia, and diabetes on premature patient death with a functioning allograft due to cardiovascular disease, it becomes clear that an immunosuppression regimen that minimizes these effects has the potential to prolong allograft and patient survival.

The higher rate of chronic allograft nephropathy in cyclosporine-treated patients in BENEFIT/BENEFIT-EXT as well as the significantly better measured GFR by a mean of at least 12.9 mL/min/1.73 m² in both belatacept groups compared with the cyclosporine group in BENEFIT suggests a trend toward improved long-term renal function. The 3-year BENEFIT data demonstrate that the difference between both belatacept groups and cyclosporine in mean calculated glomerular filtration rate (cGFR) was about 21 mL/min/1.73 m² at year 3. In BENEFIT-EXT, the 2-year mean measured GFR was 52 mL/min/1.73 m², 50 mL/min/1.73 m², and 45 mL/min/1.73 m² for the MI, LI, and cyclosporine groups, respectively (\( P = 0.28 \) MI versus cyclosporine; \( P = 0.108 \) LI versus cyclosporine). Typically, GFR declines by approximately 1–2 mL/min/1.73 m² annually in renal allografts and ultimately leads to graft failure. The BENEFIT/BENEFIT-EXT findings indicate that a higher intercept GFR and a promising GFR stage at 2 and 3 years, if sustained, would result in better preservation of renal function and ultimately in prolonged graft survival.

Blood pressure has emerged as an indicator of allograft and patient survival. Opelz et al have demonstrated that for every 10 mmHg increase in systolic blood pressure above 140 mmHg at one-year post-transplant there is an increased risk of graft failure during the following 6 years. Adjusting for renal function, there is a 15% reduction in the rate of allograft survival for each 10 mmHg increase in systolic blood pressure. For every 10 mmHg increase in blood pressure, there is not only an increased risk of graft failure but also an increased risk of death. In BENEFIT, there was...
a significant improvement of 6–9 mmHg in mean systolic blood pressure of belatacept-treated patients compared with cyclosporine-treated patients. In BENEFIT-EXT, the mean systolic blood pressure was 150 mmHg in cyclosporine-treated patients, and significantly higher than in belatacept-treated patients. The improvement in blood pressure control in belatacept-treated patients occurred despite the fact that more patients in the two cyclosporine treatment groups required at least three antihypertensive medications compared with the belatacept-treated patients. Improved blood pressure control in belatacept-treated patients will likely translate into improved long-term graft and patient survival.

Non-high-density lipoprotein cholesterol was significantly better in patients treated with belatacept compared with those who received cyclosporine. Dyslipidemia following renal transplant has been associated with greater patient death post-transplant but not graft loss; however, a lower incidence of hyperlipidemia benefits mortality due to cardiovascular events. Improvements in this risk profile will likely translate into a lower rate of cardiac events and reduce the cardiovascular mortality seen in the renal transplant population.

Avoiding NODAT has important implications for patients following transplant, including less use of diabetic medications, reduced cardiovascular risk, and improved patient and allograft survival. Interestingly, an analysis was also done to evaluate the effect of belatacept use compared with cyclosporine in patients with pre-existing diabetes. This post hoc analysis evaluated pooled data from BENEFIT and BENEFIT-EXT to assess the effect of belatacept on patient and allograft survival in this high-risk patient population. Of the 1209 patients in the two trials, 336 had pre-existing diabetes. At 12 months, the LI group demonstrated a numerically higher rate of patients surviving with a functioning graft (90.4% LI, 92.8% CNI, and 80.8% cyclosporine). However, this difference was not statistically significant. These data are intriguing because they suggest that there may be a patient and allograft survival benefit for patients with pre-existing diabetes with belatacept compared with cyclosporine. However, further studies are necessary to confirm these findings and fully elucidate the benefits belatacept may provide in this high-risk patient group.

**Conclusion**

Belatacept, as demonstrated in two large Phase III clinical trials, is noninferior to cyclosporine at one year in patient and graft survival. The incidence of acute rejection was higher in belatacept-treated patients compared with cyclosporine-treated patients. However, despite a higher incidence of rejection, belatacept-treated patients had improved mean measured GFR at one and 2 years. Except for the higher Banff grade, rejections on belatacept were not associated with poor prognostic factors for graft outcomes. Improvements in blood pressure, lipids, and GFR will likely translate into improved long-term patient and graft survival as part of a CNI-avoiding regimen. The risk of PTLD can be modified by selecting EBV-positive recipients and avoiding use of lymphocyte-depleting agents.

**Disclosure**

FV received grant support from Bristol-Myers Squibb, Princeton, NJ. DW reports no conflicts of interest in this work.

**References**


